Nested Randomized Controlled Trials in Large Databases: An Opportunity for Inflammatory Bowel Disease? - Top-Institutions - MDSpire

Nested Randomized Controlled Trials in Large Databases: An Opportunity for Inflammatory Bowel Disease?

  • By

  • Maria Jose Temido

  • Sailish Honap

  • Silvio Danese

  • Vipul Jairath

  • Fernando Magro

  • Francisco Portela

  • Laurent Peyrin-Biroulet

  • August 29, 2024

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Clinical Trials

  • #2

    Mount Sinai Hospital
    Mount Sinai Hospital

    New York, NY

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Epidemiology

  • #3

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Clinical Research

  • #4

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Clinical Trials

  • #5

    University of Toronto
    University of Toronto

    Toronto, ON

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Epidemiology

Original Source(s)

Nested Randomized Controlled Trials in Large Databases: An Opportunity for Inflammatory Bowel Disease?

  • by Maria Jose Temido, Sailish Honap, Silvio Danese, Vipul Jairath, Fernando Magro, Francisco Portela, Laurent Peyrin-Biroulet

  • August 29, 2024

Related Content

Intestinal subepithelial myofibroblasts in inflammatory bowel disease: fibroblast heterogeneity, fibrosis, and therapeutic targeting

Infection risk in inflammatory bowel disease patients treated with vedolizumab: a systematic review and meta-analysis

Commentary: SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo